MabionCD20

MabionCD20

Products

Information

This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.
Main Categories
Biopharmaceuticals
All Categories
Monoclonal Antibodies
Distribution areas
North America (USA, Canada)Europe - EU countries
Mabion SAMabion is a fully integrated CDMO offering a wide array of services associated with the development and manufacturing of protein-based biotherapeutics, including monoclonal antibodies and vaccine antigens. With 16 years' experience, Mabion offers an end-to-end solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process scale-up, large-scale manufacturing and quality control down to sterile fill-finish, packaging and serialization, bioanalytics and regulatory support.

Log in

See all the content and easy-to-use features by logging in or registering!